检索结果 - Rod Humerickhouse

  • Showing 1 - 19 results of 19
Refine Results
  1. 1
    Randomized, Phase II Study of the Thrombospondin-1-Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Soft Tissue Sarcoma

    Randomized, Phase II Study of the Thrombospondin-1-Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Soft Tissue Sarcoma 由 Laurence H. Baker, Eric K. Rowinsky, David S. Mendelson, Rod Humerickhouse, Raymond A. Knight, Jiang Qian, Robert Carr, Gary Gordon, George D. Demetri

    出版 2008
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma

    Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma 由 Scot Ebbinghaus, Maha Hussain, Nizar Tannir, Michael S. Gordon, Apurva A. Desai, Raymond A. Knight, Rod Humerickhouse, Jiang Qian, Gary Gordon, Robert A. Figlin

    出版 2007
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Safety and efficacy of navitoclax, a BCL-2 and BCL-X <sub>L</sub> inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study

    Safety and efficacy of navitoclax, a BCL-2 and BCL-X <sub>L</sub> inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study 由 Sven de Vos, John P. Leonard, Jonathan W. Friedberg, Jasmine Zain, Kieron Dunleavy, Rod Humerickhouse, John Hayslip, John C. Pesko, Wyndham H. Wilson

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy

    Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy 由 Steven Coutré, Michael Y. Choi, Richard R. Furman, Herbert Eradat, Leonard T. Heffner, Jeffrey A. Jones, Brenda Chyla, Lang Zhou, Suresh Agarwal, Tina Waskiewicz, Maria Verdugo, Rod Humerickhouse, Jalaja Potluri, William G. Wierda, Matthew S. Davids

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

    Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease 由 Andrew W. Roberts, John F. Seymour, Jennifer R. Brown, William G. Wierda, Thomas J. Kipps, Seong Lin Khaw, Dennis Carney, Simon He, David C.S. Huang, Hao Xiong, Yue Cui, Todd Busman, Evelyn McKeegan, Andrew Krivoshik, Sari H. Enschede, Rod Humerickhouse

    出版 2011
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib

    Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib 由 Jeffrey A. Jones, Michael Y. Choi, Anthony R. Mato, Richard R. Furman, Matthew S. Davids, Leonard T. Heffner, Bruce D. Cheson, Nicole Lamanna, Paul M. Barr, Herbert Eradat, Ahmad Halwani, Brenda Chyla, Ming Zhu, Maria Verdugo, Rod Humerickhouse, Jalaja Potluri, William G. Wierda, Steven Coutré

    出版 2016
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

    Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour act... 由 Wyndham H. Wilson, Owen A. O’Connor, Myron S. Czuczman, Ann S. LaCasce, John F. Gerecitano, John P. Leonard, Anil Tulpule, Kieron Dunleavy, Hao Xiong, Yi‐Lin Chiu, Yue Cui, Todd Busman, Steven W. Elmore, Saul H. Rosenberg, Andrew Krivoshik, Sari H. Enschede, Rod Humerickhouse

    出版 2010
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

    Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial 由 Jeffrey A. Jones, Anthony R. Mato, William G. Wierda, Matthew S. Davids, Michael Y. Choi, Bruce D. Cheson, Richard R. Furman, Nicole Lamanna, Paul M. Barr, Lang Zhou, Brenda Chyla, Ahmed Hamed Salem, Maria Verdugo, Rod Humerickhouse, Jalaja Potluri, Steven Coutré, Jennifer A. Woyach, John C. Byrd

    出版 2017
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

    Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia 由 John F. Seymour, Thomas J. Kipps, Barbara Eichhorst, Peter Hillmen, James D’Rozario, Sarit Assouline, Carolyn Owen, John Gerecitano, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Rod Humerickhouse, Elizabeth A. Punnoose, Yan Li, Michelle Boyer, Kathryn Humphrey, Mehrdad Mobasher, Arnon P. Kater

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    Phase I and Biomarker Study of ABT-869, a Multiple Receptor Tyrosine Kinase Inhibitor, in Patients With Refractory Solid Malignancies

    Phase I and Biomarker Study of ABT-869, a Multiple Receptor Tyrosine Kinase Inhibitor, in Patients With Refractory Solid Malignancies 由 Chiung‐Ing Wong, Tong-San Koh, Ross A. Soo, Septian Hartono, Choon Hua Thng, Evelyn McKeegan, Wei Peng Yong, Chien-Shing Chen, Soo Chin Lee, John Wong, Robert Lim, Norita Sukri, Siew-Eng Lim, Ai-Bee Ong, Joyce Steinberg, Neeraj Gupta, Rajendra Pradhan, Rod Humerickhouse, Boon-Cher Goh

    出版 2009
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

    Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors 由 Leena Gandhi, D. Ross Camidge, Moacyr Oliveira, Philip Bonomi, D. Gandara, Divis Khaira, Christine L. Hann, Evelyn McKeegan, Elizabeth Litvinovich, Philip M. Hemken, Caroline Dive, Sari H. Enschede, Cathy E. Nolan, Yi‐Lin Chiu, Todd Busman, Hao Xiong, Andrew Krivoshik, Rod Humerickhouse, Geoffrey I. Shapiro, Charles M. Rudin

    出版 2011
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

    Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia 由 Andrew W. Roberts, Matthew S. Davids, John M. Pagel, Brad S. Kahl, Soham D. Puvvada, John F. Gerecitano, Thomas J. Kipps, Mary Ann Anderson, Jennifer R. Brown, Lori A. Gressick, Shekman Wong, Martin Dunbar, Ming Zhu, Monali Desai, Elisa Cerri, Sari H. Enschede, Rod Humerickhouse, William G. Wierda, John F. Seymour

    出版 2015
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

    Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study 由 Andrew H. Wei, Stephen A. Strickland, Jing-Zhou Hou, Walter Fiedler, Tara L. Lin, Roland B. Walter, Anoop K. Enjeti, Ing Soo Tiong, Michael R. Savona, Sang‐Min Lee, Brenda Chyla, Relja Popovic, Ahmed Hamed Salem, Suresh Agarwal, Tu Xu, Kaffa Fakouhi, Rod Humerickhouse, Wan-Jen Hong, John Hayslip, Gail J. Roboz

    出版 2019
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

    Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia 由 Marina Konopleva, Daniel A. Pollyea, Jalaja Potluri, Brenda Chyla, Leah J. Hogdal, Todd Busman, Evelyn McKeegan, Ahmed Hamed Salem, Ming Zhu, Justin L. Ricker, William Blum, Courtney D. DiNardo, Tapan M. Kadia, Martin Dunbar, Rachel Kirby, Nancy Falotico, Joel D. Leverson, Rod Humerickhouse, Mack Mabry, Richard M. Stone, Hagop M. Kantarjian, Anthony Letai

    出版 2016
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

    Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study 由 John F. Seymour, Shuo Ma, Danielle M. Brander, Michael Y. Choi, Jacqueline C. Barrientos, Matthew S. Davids, Mary Ann Anderson, Anne Beaven, Steven T. Rosen, Constantine S. Tam, Betty Prine, Suresh Agarwal, Wijith Munasinghe, Ming Zhu, Leanne Lash, Monali Desai, Elisa Cerri, Maria Verdugo, Su Young Kim, Rod Humerickhouse, Gary Gordon, Thomas J. Kipps, Andrew W. Roberts

    出版 2017
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

    Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma 由 Matthew S. Davids, Andrew W. Roberts, John F. Seymour, John M. Pagel, Brad S. Kahl, William G. Wierda, Soham D. Puvvada, Thomas J. Kipps, Mary Ann Anderson, Ahmed Hamed Salem, Martin Dunbar, Ming Zhu, Franklin Peale, Jeremy A. Ross, Lori A. Gressick, Monali Desai, Su Young Kim, Maria Verdugo, Rod Humerickhouse, Gary Gordon, John F. Gerecitano

    出版 2017
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  17. 17
    Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

    Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer 由 Charles M. Rudin, Christine L. Hann, Edward B. Garon, Moacyr Oliveira, Philip Bonomi, D. Ross Camidge, Quincy Chu, Giuseppe Giaccone, Divis Khaira, Suresh S. Ramalingam, Malcolm Ranson, Caroline Dive, Evelyn McKeegan, Brenda Chyla, Barry L. Dowell, Arunava Chakravartty, Cathy E. Nolan, Niki S. Rudersdorf, Todd Busman, Mack Mabry, Andrew Krivoshik, Rod Humerickhouse, Geoffrey I. Shapiro, Leena Gandhi

    出版 2012
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    Venetoclax and obinutuzumab in chronic lymphocytic leukemia

    Venetoclax and obinutuzumab in chronic lymphocytic leukemia 由 Kirsten Fischer, Othman Al‐Sawaf, Anna-Maria Fink, Mark Dixon, Jasmin Bahlo, Simon Warburton, Thomas J. Kipps, Robert Weinkove, Sue Robinson, Till Seiler, Stephen Opat, Carolyn Owen, Javier López, Kathryn Humphrey, Rod Humerickhouse, Eugen Tausch, Lukas P. Frenzel, Barbara Eichhorst, Clemens-M. Wendtner, Stephan Stilgenbauer, Anton W. Langerak, Jacque J. M. van Dongen, Sebastian Böttcher, Matthias Ritgen, Valentin Goede, Mehrdad Mobasher, Michael Hallek

    出版 2017
    获取全文 获取全文
    Carta
    加到收藏夹
    Saved in:
  19. 19
    Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

    Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions 由 Kirsten Fischer, Othman Al‐Sawaf, Jasmin Bahlo, Anna-Maria Fink, Maneesh Tandon, Mark Dixon, Sandra Robrecht, Simon Warburton, Kathryn Humphrey, Olga Samoylova, A. M. Liberati, Javier Pinilla‐Ibarz, Stephen Opat, Liliya Sivcheva, Katell Le Dû, Laura Fogliatto, Carsten Utoft Niemann, Robert Weinkove, Sue Robinson, Thomas J. Kipps, Sebastian Böettcher, Eugen Tausch, Rod Humerickhouse, Barbara Eichhorst, Clemens‐Martin Wendtner, Anton W. Langerak, Karl-Anton Kreuzer, Matthias Ritgen, Valentin Goede, Stephan Stilgenbauer, Mehrdad Mobasher, Michael Hallek

    出版 2019
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: